Drug Profile
Dexelvucitabine
Alternative Names: beta-D-D4FC; D-D4FC; DFC; DPC-817; Reverset; RVTLatest Information Update: 23 Sep 2021
Price :
$50
*
At a glance
- Originator Emory University
- Developer Incyte Corporation; Pharmasset
- Class Antiretrovirals; Nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 31 Jan 2012 Discontinued - Preclinical for HIV infections in USA (PO)
- 17 Jan 2012 Pharmasset has been acquired by Gilead Sciences
- 09 Jul 2009 Preclinical trials in HIV infections in USA (PO)